Multiple myeloma is a type of blood cancer that appears mainly after the age of 60. Its incidence, therefore, increases with the aging of the population. In this pathology, the bone marrow, the porous structure within the bones that produces normal blo…
Patients with a rare blood cancer that has relapsed or become resistant to treatment have shown a high response rate to a potent new immunotherapy drug, in a Peter Mac-led clinical trial.
Metastatic disease—when cancer spreads from the primary tumor to other parts of the body—is the cause of most cancer deaths. While researchers understand how cancer cells escape the primary site to seed new tumors, it’s not well understood why some of …
A new cell therapy, targeting CD7 in leukemia cells, gives a potentially effective treatment for patients with T-cell acute lymphoblastic leukemia (T-ALL) who have exhausted all standard treatment options. Published in the journal Nature Medicine on 3 …
A new study published in Cell Reports Medicine reveals critical insights into the role of gamma-delta T cells across 33 cancer types, shedding light on their potential as clinical biomarkers and therapeutic targets in cancer treatment. Led by a team of…
An experimental blood test detects early-stage pancreatic cancer more effectively than other available tests, reports a new study published in Cancer Letters. The findings pave the way for further evaluation of the test in a clinical setting, an import…
In the first study to report real-world outcomes from ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR)-T therapy for multiple myeloma, patients experienced efficacy and safety results similar to those seen in clinical trials, ac…
Blood stem cells, which give rise to all of our blood cell types, undergo a quality assurance process after they’re born. As the lab of Leonard Zon, MD, director of the Stem Cell Research program at Boston Children’s, has documented, immune cells known…
Researchers at the Spanish National Cancer Research Center (CNIO) propose a new treatment for brain metastases that respond poorly, or not at all, to immunotherapy, and provide a biomarker to predict in which cases it should be used.
A Cleveland Clinic-led research collaboration between Timothy Chan, MD, Ph.D., Chair of Cleveland Clinic’s Global Center for Immunotherapy, and Bristol Myers Squibb has published the most comprehensive overview to date of how the immune system reshapes…
